Alzheimer Disease (AD) is the most common form of dementia in the world
and is a cause of infirmity in the older people. The prevalence of this disorder increases
exponentially with age ranging from approximately 2% at the age of 60-65 years to
more than 30%-35% in people older than 80 years.
AD pathological modifications begin to accumulate for years, before all typical
(emotional, physical, or cognitive) symptoms emerge. The classical hallmarks of AD
are senile plaques and neurofibrillary tangles, which consist of amyloid-β (A) and
hyper-phosphorylated tau proteins. The exact aetiology of this pathology is still unclear,
and it is considered a complex multifactorial disorder in which genetics, epigenetics and
environmental factors contribute to prompt neurons towards a premature death.
For the last 20 years, the “amyloid cascade hypothesis” has dominated research aimed
at understanding, preventing and curing the AD. Several strategies have been studied
for setting up therapies against amyloid deposits, which have been successful in curing
the disease in some animal models, but they have never been effective in human AD
patients. These failures have supported the hypothesis that the up-regulation of amyloid
precursor protein (APP) and Aβ could be necessary to respond to
inflammation/oxidative stress-associated neurodegeneration. In particular the oxidative
stress associated to the increase of free radicals have been demonstrated to be involved
in the etiopathogenesis of AD and enhanced levels of oxidative injuries markers in
cellular macromolecule (lipids, DNA, proteins) have been found in the central nervous
system and peripheral tissues of AD patients. These findings demonstrate that reactive
oxygen species (ROS) targeted therapy can be successful in AD treatment.
Epigenetics refers to all meiotically and mitotically reversible heritable changes in gene
expression which occur independently of DNA sequence, and are principally due to
changes in DNA methylation, chromatin structure and microRNA (miRNA) expression.
Emerging evidences from animal and human studies suggest that epigenetic
mechanisms are involved in learning and memory, and that many of biological
pathways dysregulated in AD are controlled through epigenetic modifications. This
rapidly expanding field of neuroepigenetics seems to be particularly promising in
identifying new aspects and, above all, new therapeutic strategies for treating this
disorder. The approval of epigenetic drugs for the treatment of other diseases (like
cancer) opens the door for the development of similar drugs also for AD.
Keywords: Alzheimer’s Disease, amyloid plaques, antioxidant, DNA
methylation, epigenetics, free radicals, histone modifications, metals,
mitochondria, microRNA, oxidative stress, reactive nitrogen species (RNS), ROS.
